These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 7875148)

  • 41. [Acute pancreatitis during treatment with meglumine antimoniate (Glucantime)].
    Barthet M; Brunet P; Bernard JC; Dussol B; Rodor F; Jouglard J; Berland Y; Sahel J
    Gastroenterol Clin Biol; 1994; 18(1):90-2. PubMed ID: 8187998
    [No Abstract]   [Full Text] [Related]  

  • 42. Very low doses of GM-CSF administered alone or with erythropoietin in aplastic anemia.
    Kurzrock R; Talpaz M; Gutterman JU
    Am J Med; 1992 Jul; 93(1):41-8. PubMed ID: 1626572
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis.
    Andersen EM; Cruz-Saldarriaga M; Llanos-Cuentas A; Luz-Cjuno M; Echevarria J; Miranda-Verastegui C; Colina O; Berman JD
    Am J Trop Med Hyg; 2005 Feb; 72(2):133-7. PubMed ID: 15741547
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow-up studies (up to 10 years).
    Oliveira-Neto MP; Schubach A; Mattos M; Goncalves-Costa SC; Pirmez C
    Am J Trop Med Hyg; 1997 Dec; 57(6):651-5. PubMed ID: 9430521
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment costs and quality of life with granulocyte-macrophage colony-stimulating factor in patients with antineoplastic therapy-related febrile neutropenia. Results of a randomised placebo-controlled trial.
    Uyl-de Groot CA; Vellenga E; de Vries EG; Löwenberg B; Stoter GJ; Rutten FF
    Pharmacoeconomics; 1997 Sep; 12(3):351-60. PubMed ID: 10170460
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Visceral leishmaniasis in clinical practice.
    Davidson RN
    J Infect; 1999 Sep; 39(2):112-6. PubMed ID: 10609527
    [No Abstract]   [Full Text] [Related]  

  • 48. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors.
    Mayordomo JI; Rivera F; Díaz-Puente MT; Lianes P; Colomer R; López-Brea M; López E; Paz-Ares L; Hitt R; García-Ribas I
    J Natl Cancer Inst; 1995 Jun; 87(11):803-8. PubMed ID: 7540696
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A randomized trial of granulocyte-macrophage colony-stimulating factor in neonates with sepsis and neutropenia.
    Bilgin K; Yaramiş A; Haspolat K; Taş MA; Günbey S; Derman O
    Pediatrics; 2001 Jan; 107(1):36-41. PubMed ID: 11134431
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antimony plus recombinant human granulocyte-macrophage colony-stimulating factor applied topically in low doses enhances healing of cutaneous Leishmaniasis ulcers: a randomized, double-blind, placebo-controlled study.
    Santos JB; de Jesus AR; Machado PR; Magalhães A; Salgado K; Carvalho EM; Almeida RP
    J Infect Dis; 2004 Nov; 190(10):1793-6. PubMed ID: 15499535
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of cutaneous leishmaniasis with a combination of allopurinol and low-dose meglumine antimoniate.
    Momeni AZ; Reiszadae MR; Aminjavaheri M
    Int J Dermatol; 2002 Jul; 41(7):441-3. PubMed ID: 12121563
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Failure of both azithromycin and antimony to treat cutaneous leishmaniasis in Manaus, AM, Brazil.
    Teixeira AC; Paes MG; Guerra Jde O; Prata A; Silva-Vergara ML
    Rev Inst Med Trop Sao Paulo; 2008; 50(3):157-60. PubMed ID: 18604416
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Should we continue to indicate meglumine antimoniate as first-line treatment for cutaneous leishmaniasis in Tunisia.
    Mlika RB; Hamida MB; Hammami H; Jannet SB; Badri T; Fenniche S; Mokhtar I
    Dermatol Ther; 2012; 25(6):615-8. PubMed ID: 23210761
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of American cutaneous leishmaniasis: a comparison between low dosage (5 mg/kg/day) and high dosage (20 mg/kg/day) antimony regimens.
    Oliveira-Neto MP; Schubach A; Mattos M; Gonçalves-Costa SC; Pirmez C
    Pathol Biol (Paris); 1997 Jun; 45(6):496-9. PubMed ID: 9309267
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Hematopoietic growth factor (GM-CSF) after autologous bone marrow transplantation. A randomized, double-blind, multicenter study in 91 cases of non-Hodgkin's malignant lymphomas].
    Gorin NC; Coiffier B; Hayat M; Fouillard L; Kuentz M; Flesch M; Colombat P; Boivin P; Slavin S; Lemarié JC
    Presse Med; 1993 Jan; 22(3):109-20. PubMed ID: 8493215
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Systemic Meglumine Antimoniate in Cutaneous Leishmaniasis of Children: Clinical and Laboratory Complications.
    Layegh P; Khademi Z; Afzal Aghaee M; Moghiman T
    J Pediatric Infect Dis Soc; 2015 Dec; 4(4):356-8. PubMed ID: 26582874
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma.
    Advani R; Chao NJ; Horning SJ; Blume KG; Ahn DK; Lamborn KR; Fleming NC; Bonnem EM; Greenberg PL
    Ann Intern Med; 1992 Feb; 116(3):183-9. PubMed ID: 1345803
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetic and parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted to multiple dose treatment with liposome-encapsulated meglumine antimoniate.
    Schettini DA; Costa Val AP; Souza LF; Demicheli C; Rocha OG; Melo MN; Michalick MS; Frézard F
    Braz J Med Biol Res; 2005 Dec; 38(12):1879-83. PubMed ID: 16302103
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of aminosidine administered alone or in combination with meglumine antimoniate for the treatment of experimental visceral leishmaniasis caused by Leishmania infantum.
    Gangneux JP; Sulahian A; Garin YJ; Derouin F
    J Antimicrob Chemother; 1997 Aug; 40(2):287-9. PubMed ID: 9301998
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The renal transplant patient with visceral leishmaniasis who could not tolerate meglumine antimoniate-cure with ketoconazole and allopurinol.
    Hueso M; Bover J; Serón D; Gil-Vernet S; Rufí G; Alsina J; Grinyó JM
    Nephrol Dial Transplant; 1999 Dec; 14(12):2941-3. PubMed ID: 10570102
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.